Literature DB >> 3535868

Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique.

H M Lokhorst, S E Boom, B J Bast, R E Ballieux.   

Abstract

A new technique is described in which plasma cells actively synthesizing DNA can be identified in a heterogeneous cell population such as bone marrow. This method uses bromodeoxyuridine (BrdU) and a fluorescent monoclonal antibody against BrdU in combination with cytoplasmic staining for immunoglobulin (Ig). In 26 patients with monoclonal gammopathy (MG) the plasma cell labelling index (LI) as determined by this immunofluorescent method was compared with the tritiated thymidine (3H-TdR) LI. No difference in sensitivity was found between the two methods. As the determination of the plasma cell LI with the BrdU/anti BrdU method is easy to perform and results can be obtained within 4 h, this immunofluorescent method seems to be an attractive alternative to the laborious time-consuming classic 3H-TdR LI.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535868     DOI: 10.1111/j.1365-2141.1986.tb04119.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.

Authors:  Jeremy T Larsen; Cheng E Chee; John A Lust; Philip R Greipp; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

2.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Thomas Hielscher; Jérôme Moreaux; Tobias Messner; Anja Seckinger; Axel Benner; John D Shaughnessy; Bart Barlogie; Yiming Zhou; Jens Hillengass; Uta Bertsch; Kai Neben; Thomas Möhler; Jean François Rossi; Anna Jauch; Bernard Klein; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

3.  Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.

Authors:  H M Lokhorst; S E Boom; B J Bast; P J Peters; T F Tedder; J Gerdes; E Petersen; R E Ballieux
Journal:  J Clin Invest       Date:  1987-05       Impact factor: 14.808

4.  Two-colour immunoenzymatic technique using sequential staining by APAAP to evaluate two cell antigens.

Authors:  R Burgess; K Hyde; P J Maguire; P R Kelsey; J A Yin; C G Geary
Journal:  J Clin Pathol       Date:  1992-03       Impact factor: 3.411

5.  Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.

Authors:  Atsushi Isoda; Kyoichi Kaira; Masanori Iwashina; Noboru Oriuchi; Hideyuki Tominaga; Shushi Nagamori; Yoshikatsu Kanai; Tetsunari Oyama; Takayuki Asao; Morio Matsumoto; Morio Sawamura
Journal:  Cancer Sci       Date:  2014-10-09       Impact factor: 6.716

6.  Induction of malignant plasma cell proliferation by eosinophils.

Authors:  Tina W Wong; Hirohito Kita; Curtis A Hanson; Denise K Walters; Bonnie K Arendt; Diane F Jelinek
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

7.  Abnormal PTBP1 Expression Sustains the Disease Progression of Multiple Myeloma.

Authors:  Hua Bai; Bing Chen
Journal:  Dis Markers       Date:  2020-06-18       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.